Long-term safety and efficacy of the recombinant human growth hormone omnitrope® in the treatment of Spanish growth hormone deficient children: Results of a phase III study

摘要

Introduction This phase III study in growth hormone (GH) deficient (GHD) children with growth retardation was designed to demonstrate the safety and efficacy of longterm treatment with the recombinant human GH Omnitrope® (Sandoz BioPharmaceuticals, Holzkirchen, Germany).